-Feng-Ting Liu Researcher Activity Profile

Research Author Detailed Information 

Feng-Ting Liu Publication Rate By Year

Feng-Ting Liu has published 5 paper(s) in 2006, 17 paper(s) in 2007, 2 paper(s) in 2008, for a total of 24 research publications in total.

Feng-Ting Ft Liu Author Information

LAST NAME: liu

FIRST NAME: Feng-Ting

INITIALS: ft

AFFILIATION:

Papers

Feng-Ting Liu's Publication Record

1. [The modulating effect of proapoptotic protein Bax on the resistance of malignant lymphoma cells to tumor necrosis factor related apoptosis inducing ligand-induced apoptosis] Year Published: 2007
Abdominal Department of Tianjin Cancer Hospital, Tianjin 300060, China.
2. Molecular basis of interaction between NG2 proteoglycan and galectin-3. Year Published: 2006
Burnham Institute, Developmental Neurobiology Program, La Jolla, California 92037, USA. ywen@burnham.org
3. [Effects of chemotherapy in recurrent endometrial carcinoma] Year Published: 2006
Center of Gynecologic Oncology, Peking University People's Hospital, Beijing 100044, China.
4. Cell mechanics using atomic force microscopy-based single-cell compression. Year Published: 2006
Chemistry Department, University of California, Davis, California 95616, USA.
5. Role of galectin-3 in mast cell functions: galectin-3-deficient mast cells exhibit impaired mediator release and defective JNK expression. Year Published: 2006
Department of Dermatology, School of Medicine, University of California-Davis, Sacramento, CA 95817, USA.
6. The COOH-terminal globular domain of fibrinogen gamma chain suppresses angiogenesis and tumor growth. Year Published: 2006
Department of Dermatology, University of California-Davis Medical Center, Sacramento, CA 95817, USA.
7. Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. Year Published: 2007
Endocrine Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
8. An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Year Published: 2007
Department of Immunopathology, Institute of Biology and Experimental Medicine (IBYME/ CONICET), Buenos Aires, Argentina. gabyrabi@ciudad.com.ar
9. Inhibition of Advanced Glycation and Absence of Galectin-3 Prevent Blood-Retinal Barrier Dysfunction during Short-Term Diabetes. Year Published: 2007
Centre for Vision Science, Queen's University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, Northern Ireland, UK.
10. The role of galectin-3 in promotion of the inflammatory response. Year Published: 2007
Department of Dermatology, University of California, Davis, School of Medicine, Sacramento, California, USA. fliu@ucdavis.edu.
11. Galectin-3 Functions as an Adhesion Molecule to Support Eosinophil Rolling and Adhesion under Conditions of Flow. Year Published: 2007
Division of Vascular Biology, La Jolla Institute for Molecular Medicine, San Diego, CA 92121.
12. The role of galectin-3 in promotion of the inflammatory response. Year Published: 2007
Department of Dermatology, University of California, Davis, School of Medicine, Sacramento, California 95816, USA. fliu@ucdavis.edu
13. Dermal immunopathology: from genetics to effector mechanisms. Year Published: 2007
Department of Medical Microbiology and Immunology, University of Toledo College of Medicine, Toledo, OH, USA, akira.takashima@utoledo.edu.
14. Mast cells and immunological skin diseases. Year Published: 2007
Department of Dermatology, School of Medicine, University of California, Davis, 3301 C Street, Suite 1400, Sacramento, CA, 95816, USA, fliu@ucdavis.edu.
15. The role of galectin-3 in promotion of the inflammatory response. Year Published: 2007
Department of Dermatology, University of California, Davis, School of Medicine, Sacramento, California 95816, USA. fliu@ucdavis.edu
16. Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. Year Published: 2007
Division of Vascular Biology, La Jolla Institute for Molecular Medicine, San Diego, CA 92121, USA.
17. Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. Year Published: 2007
Endocrine Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
18. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Year Published: 2007
Centre for Vision Science, Queen's University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, Northern Ireland, UK.
19. Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. Year Published: 2007
Division of Vascular Biology, La Jolla Institute for Molecular Medicine, San Diego, CA 92121, USA.
20. Dermal immunopathology: from genetics to effector mechanisms. Year Published: 2007
Department of Medical Microbiology and Immunology, University of Toledo College of Medicine, Toledo, OH, USA. akira.takashima@utoledo.edu
21. Mast cells and immunological skin diseases. Year Published: 2007
Department of Dermatology, School of Medicine, University of California Davis, Sacramento, CA 95816, USA.
22. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Year Published: 2007
Centre for Vision Science, Queen's University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, Northern Ireland, UK.
23. Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Year Published: 2008
Centre for Haematology, Institute of Cell and Molecular Science, Departments of Haematology and Haemato-Oncology, Queen Mary University of London, UK. s.g.agrawal@qmul.ac.uk
24. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Year Published: 2008
Centre for Haematology, Institute of Cell and Molecular Sciences, Barts and the London, Queen Mary University of London, 4 Newark Street, London, UK.